Solventum Q2 Earnings Call Highlights

Second-quarter results exceeded expectations: Sales reached $2.2 billion, with organic growth of 9.5%, while adjusted performance benefited from advanced ERP-related orders and a $100 million tariff refund. Excluding those benefits, organic growth was approximately 4% and EPS was estimated at $1.73. Solventum raised its 2026 outlook: The company now expects 2.5%–3% organic sales growth, a 22.2%–22.7% operating margin, adjusted EPS of $7.10–$7.20 and free cash flow of $200 million–$300 million. Third-quarter growth is expected to decline temporarily as roughly $125 million of advanced orders reverse. The company is pursuing a separation of Health Information Systems: Solventum is evaluating a spin-off or sale to sharpen its focus on MedSurg and Dental, while citing HIS’s growth potential in AI-driven coding and international markets. Solventum Nears Inflection Point As It Begins to Unlock Value Solventum NYSE: SOLV reported second-quarter results that exceeded its internal expectations, supported by broad-based segment performance, planned order activity ahead of an ERP cutover and a tariff refund benefit. The company also announced plans to separate its Health Information Systems, or HIS, business as part of a broader effort to sharpen its focus on medical technology markets. Chief Executive Officer Bryan Hanson said the company delivered ahead of plan on both revenue and earnings, citing specialized commercial teams, product innovation and operating discipline. He said the company remains on track to achieve its long-range plan earlier than originally expected. "The quarter came in ahead of plan, top and bottom line," Hanson said. "Organic growth and EPS were both ahead of expectations." Second-quarter sales totaled $2.2 billion, rising 9.5% organically from a year earlier and 2.2% on a reported basis. Foreign exchange added 100 basis points to reported growth, while acquisitions and divestitures reduced reported growth by 830 basis points, primarily due to the sale of the Purification & Filtration business. The impact was partly offset by the Acera acquisition. Chief Financial Officer Wayde McMillan said revenue growth was primarily volume-driven and included approximately $125 million of customer orders advanced ahead of the company’s North America ERP cutover. These orders are expected to mostly reverse in the third quarter. On a normalized basis, excluding the ERP-related timing effect, SKU rationalization headwinds and a partial separation timing benefit, Solventum estimated organic sales growth at about 4% for the quarter. Pricing remained within the company’s expected range of plus or minus 1%. MedSurg: Sales were $1.4 billion, with organic growth of 8.9%. ERP advanced orders accounted for roughly 700 basis points of growth, primarily in Infection Prevention and Surgical Solutions. Dental Solutions: Sales were $396 million, with organic growth of 15.2%. Advanced orders contributed about 10 percentage points of growth, while new product launches supported underlying performance. Health Information Systems: Sales were $354 million, with organic growth of 5.4%, driven by revenue cycle management solutions, customer retention and commercial execution. Hanson said Solventum has not experienced the market softness or procedure-volume pressure cited by some healthcare companies. He said the company continues to see favorable conditions across MedSurg, Dental and HIS, although management is monitoring broader industry trends.